Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    OKYO Pharma Limited

    NASDAQ: OKYO · Real-Time Price · USD
    2.43
    0.01 (0.21%)
    At close: Jun 27, 2025, 3:59 PM
    2.48
    2.06%
    After-hours: Jun 27, 2025, 07:14 PM EDT
    0.21%
    Bid 2.41
    Market Cap 90.94M
    Revenue (ttm) n/a
    Net Income (ttm) -7.09K
    EPS (ttm) -0.38
    PE Ratio (ttm) -6.39
    Forward PE -18.62
    Analyst Buy
    Ask 2.53
    Volume 37,339
    Avg. Volume (20D) 154,793
    Open 2.41
    Previous Close 2.42
    Day's Range 2.41 - 2.44
    52-Week Range 0.81 - 3.11
    Beta -4.30

    About OKYO

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol OKYO
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for OKYO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    5 months ago
    +2.88%
    OKYO Pharma shares are trading higher after the co... Unlock content with Pro Subscription
    5 months ago
    +0%
    OKYO Pharma shares are trading higher after the company announced it received $1.4 million in non-dilute funding.
    news image

    2 weeks ago · proactiveinvestors.com

    OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts

    Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment i...

    news image

    2 weeks ago · accessnewswire.com

    Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

    Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap se...

    news image

    1 month ago · proactiveinvestors.com

    OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit

    OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference i...

    news image

    1 month ago · proactiveinvestors.com

    OKYO moves toward FDA talks after eye drug trial – ICYMI

    OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101) for neuropathic corneal pain. The company said the 48-patien...

    news image

    2 months ago · proactiveinvestors.com

    OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain

    OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular c...

    news image

    2 months ago · proactiveinvestors.com

    OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain

    OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic corneal pain. The company has chosen to end its Phas...

    news image

    2 months ago · proactiveinvestors.com

    OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMI

    OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company's recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the c...

    news image

    3 months ago · proactiveinvestors.com

    OKYO Pharma reports long-term shelf stability of corneal pain treatment

    OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a half years in single-use ampoules. The biopharmaceutical company's confi...

    Add to Watchlist